Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats
- 1 October 2000
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 42 (4), 337-343
- https://doi.org/10.1006/phrs.2000.0695
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- PHARMACOKINETICS OF DOXORUBICIN INCORPORATED IN SOLID LIPID NANOSPHERES (SLN)Pharmacological Research, 1999
- Biodegradable Nanoparticles Containing Doxorubicin-PLGA Conjugate for Sustained ReleasePharmaceutical Research, 1999
- Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticlesInternational Journal of Pharmaceutics, 1998
- An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluationBritish Journal of Cancer, 1996
- Long circulating microparticulate drug carriersAdvanced Drug Delivery Reviews, 1995
- Biodegradable Long-Circulating Polymeric NanospheresScience, 1994
- Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomesFEBS Letters, 1990
- Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticlesCancer Chemotherapy and Pharmacology, 1990
- High-performance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissueJournal of Chromatography B: Biomedical Sciences and Applications, 1988
- Synthesis of daunorubicin analogs with novel 9-acyl substituentsJournal of Medicinal Chemistry, 1979